<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73270">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151838</url>
  </required_header>
  <id_info>
    <org_study_id>TRCS PMTCT</org_study_id>
    <nct_id>NCT02151838</nct_id>
  </id_info>
  <brief_title>The Thai Red Cross Society Prevention of Mother-To-Child Transmission of HIV (TRCS PMTCT) Program</brief_title>
  <official_title>The Thai Red Cross AIDS Research Centre</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thai Red Cross AIDS Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thai Red Cross AIDS Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and the efficacy of Highly Active Anti-Retroviral Treatment (HAART) for
      the Prevention of Mother-To-Child Transmission of HIV (PMTCT)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To describe characteristics of HIV-infected pregnant women who request HAART from the
           Thai Red Cross Society PMTCT (TRCS PMTCT) program

        2. To study adverse pregnancy outcomes among HIV-infected pregnant women who receive HAART

        3. To study adverse events in infants born to women who receive HAART during pregnancy

        4. To evaluate risk factors for HAART-related toxicities and for perinatal HIV
           transmission

        5. To establish the pilot model of care for HIV-infected pregnant women in middle income
           country
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-infected pregnant women</measure>
    <time_frame>18 months</time_frame>
    <description>Choose to start HAART according to protocol and do not want to receive antiretroviral treatment provided by the other health care systems</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>HIV-infected Pregnant Women Who Request HAART From the TRCSPMTCT</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be HIV-infected pregnant women who request HAART from the TRCS
        PMTCT program. These pregnant women will be under the care of the health care teams in 30
        hospitals throughout Thailand which have registered with the TRCS PMTCT program since
        April 2004
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Volunteers meeting all of the following criteria will be considered eligible for
        enrollment in the study:

          1. HIV-infected pregnant women (as defined by the hospital)

          2. Choose to start HAART according to protocol and do not want to receive antiretroviral
             treatment provided by the other health care systems

          3. Understand the study and sign informed consent form. Persons who cannot read will
             have the consent form read to them by a study staff and they can give informed
             consent by using thumb print.

          4. Availability for follow-up for the planned study duration

        Exclusion Criteria:

        Volunteers meeting any of the following criteria will be excluded from the study:

        1.Persons who have a history of a medical or psychiatric disorder by interview and
        physical examination according to standard practices, that in the judgment of the treating
        physician, would interfere with or serve as a contraindication to adherence to the study
        protocol or ability to give informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Pathumwan,</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>January 17, 2017</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-infected pregnant women who request HAART from the TRCSPMTCT</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
